Boston Scientific-sponsored gBETA Medtech Accelerator Announces Fall 2018 Cohort

gBETA Medtech, a program of the nationally ranked accelerator gener8tor, has selected six startups for its Fall 2018 cohort from an international applicant pool. gBETA Medtech is funded by Boston Scientific with additional support from Mayo Clinic, the University of Minnesota and Medical Alley Association.

“gBETA Medtech’s success this year is a testimony to the demand for even greater collaboration between early-stage ventures, influential institutions and corporate leaders,” said Dave Knapp, vice president, Corporate Research at Boston Scientific. “As we build more and closer relationships across this ecosystem, we move closer to our ultimate goal: an even greater impact on patient care, lives changed and lives saved.”

gBETA Medtech is a free, seven-week accelerator that works with medical device, healthcare-related software, biotech, and diagnostics startups for no fees and no equity. Each gBETA program is capped at six companies to ensure meaningful engagement with sponsors and other resources. Participants receive intensive and individualized coaching and access to physicians, researchers, successful entrepreneurs, angel investors, venture capitalists, and industry experts. The program is designed to help startups gain early customer traction on their product or idea, and establish metrics that can make them competitive applicants for full-time, equity-based accelerators or seed investment.

“Demand for programs like ours is only growing in the wake of our first two cohorts’ success. We believe that the solutions these companies offer to address diverse clinical needs have the potential to be truly disruptive, and we can’t wait to integrate these companies into Medical Alley,” said Adam Choe, director of gBETA Medtech.

The gBETA Medtech Fall 2018 cohort includes:

• CorInnova Houston, Texas designs and develops a revolutionary soft robotic non-blood contacting biventricular cardiac assist device for the treatment of heart failure (HF) that would eliminate 40% of the adverse events associated with existing cardiac assist devices.

  CEO: William Altman | william.altman@corinnova.com | www.corinnova.com

• Drug Free Therapeutix (Indianapolis, Indiana) designs and develops an intelligent, networked non-invasive closed-loop vagal nerve stimulation (VNS) technology that uses artificial intelligence
  and machine learning to treat a variety of pain and gastrointestinal disorders.

  CEO: Stephen Hourigan | shourigan@dftxllc.com | www.drugfreetherapeutix.com  

• HabitAware makes Keen, a smart bracelet that helps people manage compulsive behaviors including trichotillomania (hair pulling), skin picking, nail biting and more.

  CEO: Sameer Kumar | sameer@habitaware.com | www.habitware.com 

• Nutrimedy (Boston, Massachusetts) improves the outdated care delivery model for clinical nutrition connecting patients with expert registered dietitians to provide education, support, and counseling for over 50 conditions through a web platform and mobile app.
  CEO: Karolina Starczak | karolina@nutrimedy.com | www.nutrimedy.com

• Phraze (San Francisco, California) automates physician electronic medical record (EMR) data entry and documentation requirements utilizing an AI scribe.

  Co-Founder: Brandon McCutcheon | brandon@phraze.co  | www.phraze.co

• Vital Health Links Woodbury specializes in helping medical practices and healthcare organizations realize new revenue and improve quality metrics through Medicare’s Chronic Care Management program.

  CEO: Saurin Patel | saurin@vitalhealthlinks.com | www.vitalhealthlinks.com

For more information on the program and ways to get involved, visit www.gbetamedtech.com.